Affimed Names Shawn M. Leland as New Chief Executive Officer
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to empowering patients in their battle against cancer, has announced the appointment of Shawn M. Leland, PharmD, RPh, as its new Chief Executive Officer (CEO). This strategic decision aligns with the company's goal of advancing its innovative pipeline of cancer therapies. Dr. Andreas Harstrick will continue in his role as Chief Medical Officer (CMO) following his time as acting CEO.
Leadership Experience and Professional Background
Shawn Leland brings with him over 15 years of significant experience in the pharmaceutical and biotechnology industries. His impressive track record includes successfully leading the development of new oncology therapies, securing substantial funding for biotech companies, and forming crucial strategic partnerships. His leadership skills are expected to be pivotal in guiding Affimed’s growth and shaping its corporate strategy.
Notable Achievements
Prior to joining Affimed, Shawn held the position of Interim CEO and Board Director at ForeBio, where he successfully guided the company through a phase 2 study and managed a notable $75 million Series D financing round. He also founded Elevation Oncology in July 2019, serving initially as Chief Business Officer and later as CEO until January 2023. During his tenure, he played a key role in advancing targeted oncology therapeutics and raised over $200 million, including a $100 million IPO.
Previous Industry Positions
From 2017 to 2019, Shawn led Business Development at Verastem Oncology and held a similar position at Argos Therapeutics from 2013 to 2017. His significant contributions in these roles helped shape the corporate development strategies of both companies, leading to numerous partnerships and licensing agreements. Shawn began his career at ARIAD Pharmaceuticals and Eli Lilly, where he gained valuable insights into the industry.
Shawn's Vision for Affimed’s Future
Expressing his excitement about his new role, Shawn remarked, “Affimed has a strong pipeline featuring three clinical-stage assets, all of which have shown clinical proof of concept. This reinforces our mission to utilize the innate immune system in cancer treatment.” He highlighted his commitment to leading the company toward achieving key milestones, ensuring that innovative therapies reach patients in need while maximizing shareholder value.
Comments from the Supervisory Board
Dr. Thomas Hecht, Chairman of Affimed’s Supervisory Board, stated, “We are excited to welcome Shawn as our new CEO. His proven leadership and entrepreneurial spirit in the biotech sector, especially in challenging situations, instills confidence in his vision for Affimed’s future.” He also recognized Dr. Harstrick's valuable contributions during his interim leadership, which helped guide the company into a focused clinical development phase.
Conclusion
With Shawn M. Leland leading the way, Affimed is well-positioned to further its innovative goals in immuno-oncology. The company anticipates reaching critical clinical milestones and expanding its therapeutic offerings to benefit patients while enhancing shareholder value.
Frequently Asked Questions
Who is the new CEO of Affimed?
Shawn M. Leland has been appointed as the new CEO of Affimed N.V.
What previous experience does Shawn Leland have?
Shawn has over 15 years of experience in biotechnology, previously serving as Interim CEO of ForeBio and founding Elevation Oncology.
What does Affimed specialize in?
Affimed specializes in immuno-oncology, aiming to harness the innate immune system to develop therapies for cancer treatment.
What is the significance of Shawn's appointment?
His appointment signals a strong commitment to advancing Affimed’s clinical programs and maximizing growth potential in a competitive market.
How has Affimed positioned itself in the oncology sector?
Affimed has developed a robust pipeline with three clinical-stage assets, demonstrating strong potential and validating its strategic approach.
